Lady of the Night (Cestrum nocturnum L.): A Comprehensive Reference
1. Nomenclature, Identity, and Botanical Description
1.1 Taxonomic Identity and the "Lady of the Night" Name Problem
The common name "Lady of the Night" is most widely and consistently applied to Cestrum nocturnum L., an evergreen woody shrub in the family Solanaceae (the nightshade or potato family). The species is also known as night-blooming jasmine, night-blooming jessamine, night-scented jessamine, night-scented cestrum, and poisonberry; in Urdu it is called raat ki rani ("queen of the night"). Despite the common name, the species is not a "true jasmine" and is not of the genus Jasminum.
The same common name — "Lady of the Night" — is also applied to Brunfelsia americana L., another member of the Solanaceae, which is native to the West Indies. In some places Brunfelsia americana is known as Lady of the Night, though a number of other scented plants have also been given this name. Because the two species are botanically distinct and possess different chemical profiles, the remainder of this article focuses on Cestrum nocturnum as the primary subject of pharmacological and ethnobotanical research. Where Brunfelsia americana is relevant it is noted separately.
1.2 Botanical Characterization of Cestrum nocturnum
The plant is an evergreen woody shrub with slender branches growing to 4 m (13 ft) tall, is multi-branched and heavily foliated, with simple, narrow lanceolate leaves 6–20 cm long and 2–4.5 cm broad, smooth and glossy, with an entire margin. The flowers are greenish white, with a slender tubular corolla 2–2.5 cm long with five acute lobes, 10–13 mm in diameter when open at night, produced in cymose inflorescences. The fruit is a berry 10 mm long by 5 mm in diameter.
The Latin specific epithet nocturnum means "at night" and refers to the plant's habit of blooming at night. The genus name Cestrum is thought to be derived from the Greek word kestron, for similarity to a plant of that name, or kestrum, a tool used for engraving, which the plant's anthers resemble.
1.3 Geographic Distribution and Naturalization
Cestrum nocturnum is native to Mexico, Central America, and northern South America, and is naturalized in South Asia. It is widely naturalized in tropical and subtropical regions throughout the world, including Australia, southern China, and the southernmost United States. This plant has escaped cultivation and is considered an aggressive weed or invasive in many parts of Oceania, including Australia, New Zealand, Fiji, French Polynesia, New Caledonia, and Samoa.
1.4 Common Names Across Languages
In Spanish the plant is known as dama de noche; in French as cestreau nocturne; in German as Nachtjasmin. In India, particularly in Ayurvedic and folk contexts, it is called raat ki rani (queen of the night). The plant is widely distributed in Fujian, Guangdong, and Yunnan provinces as well as Guangxi Zhuang Autonomous Region, China, where it has long been used in traditional Chinese medicine (TCM) to treat digestive diseases.
1.5 Common Forms and Preparations
Cestrum nocturnum is used in several forms across different traditions and research contexts:
- Decoctions and infusions of leaves and bark, taken orally or used as topical baths, documented in traditional Mesoamerican and South Asian medicine.
- Leaf and aerial-part extracts prepared by hydroalcoholic, ethanolic, methanolic, or aqueous extraction methods — the forms most commonly used in laboratory pharmacological studies.
- Essential oil, obtained by steam distillation of the flowers (yield approximately 0.34% w/w), analyzed by GC-MS to identify 47 different compounds representing 93.28% of the total oil.
- Floral absolute, an aromatic concentrate used in perfumery and — to a limited extent — in aromatherapy. The absolute of Cestrum nocturnum has been analyzed by GC and GC/MS, with more than 130 compounds detected and more than 100 identified.
- Topical ointments prepared from leaf extracts, investigated in animal wound healing models.
- Attar (traditional Indian concentrated perfume): it is made into a rare attar (raat ki rani) used in Indian and Middle Eastern perfumery.
2. Traditional and Historical Use
2.1 Mesoamerican Traditions
The Yucatec Maya use decoctions of the plant as medicinal baths to treat cold sweats as well as a curious illness known as ak'ahkilka ("night sweats"). In Mexican folk medicine, an extract of the leaves is used as an antispasmodic, especially in the treatment of epilepsy.
In the mythology of the Lacandon of Naha', who have preserved the pre-Hispanic cosmology of the Maya, the lord of death (Kisin) was said to have been born from a flower of Cestrum nocturnum; it is possible that the ancient Maya may have used the plant in necromantic rituals. Apart from this mythology, no traditional use of the plant for psychoactive purposes is currently documented with ethnographic certainty.
2.2 Traditional Chinese Medicine
In traditional Chinese medicine (TCM), Cestrum nocturnum has long been used to treat digestive diseases for centuries. Numerous studies have identified pharmacological actions including analgesic action, central inhibitory action, and antidiabetic activity.
2.3 South Asian Ethnobotanical Use
Research articles from the 1970s in Indian journals surveyed local uses, particularly in Andhra Pradesh, where elderly practitioners used crushed leaves for mild skin irritations. Over time these practices spread to urban herbal shops, where essential oils extracted from the flowers are marketed for sleep-friendly aromatherapy. Among ethnobotanical surveys in South India during the early 2000s, some tribal healers combined raat ki rani with coconut water to produce a topical compress for joint stiffness. In India, where the plant is called raat ki rani, it is planted near windows and terraces specifically for its evening fragrance.
2.4 Other Documented Ethnobotanical Uses
The plant is made into a rare attar used in Indian and Middle Eastern perfumery. Across regions, oral traditions speak of boiling the blooms for steam inhalation during colds. In a rare discussion of traditional entheogenic use of the plant, Müller-Ebeling, Rätsch, and Shahi describe shamanic use of Cestrum nocturnum in Nepal. Common folk applications documented in the ethnobotanical literature also include treatment of anxiety and epilepsy-like conditions, and use for skin disorders. Pharmacological studies have documented its use for anti-inflammatory, analgesic, antimicrobial, anticonvulsant, and sedative properties, and common applications involve the treatment of ailments like epilepsy, anxiety, and skin disorders.
3. Key Phytochemical Constituents
3.1 Overview of Chemical Classes
Several phytochemical studies have demonstrated the presence of important bioactive compounds in different parts of the plant: alkaloids, flavonol glycosides, steroidal saponins, fatty acids, essential oils, phenols, and others. Qualitative analysis has revealed the presence of alkaloids, glycosides, saponins, and flavonoids in the species.
3.2 Steroidal Glycosides and Saponins
Steroidal glycosides are the most extensively characterized class of compounds isolated from C. nocturnum leaves. A new steroidal saponin named nocturnoside A has been isolated from the methanolic extract of the fresh leaves of Cestrum nocturnum and has been characterized by ¹³C NMR spectroscopy as a spirostanol-type compound. Further phytochemical analysis aimed at the steroidal glycoside constituents of the leaves resulted in the isolation of eight new steroidal glycosides classified into a spirostanol saponin, a furostanol saponin, a pseudo-furostanol saponin, two pregnane glycosides, two cholestane glycosides, and a pregnane-carboxylic acid γ-lactone glycoside, plus two known spirostanol glycosides.
Phytochemical analysis of the leaves has also resulted in the isolation of two new flavonol glycosides and seven steroidal saponins, including four new ones. The flowers' alcohol extract contains cytotoxic steroids.
3.3 Flavonoids
Several flavonoid compounds have been identified in leaf extracts. Quercetin has been researched for its anti-inflammatory properties, while kaempferol has demonstrated potential in the prevention of cancer. Flavonol glycosides co-occur with the steroidal saponin fraction and have been subjected to cytotoxicity testing against cancer cell lines. The plant contains many flavonoids and sterols/triterpenoids as its main constituents, which are known bioactive principles for antidiabetic potential; flavonoids are also known to regenerate damaged β-cells in diabetic animal models.
3.4 Alkaloids
Concerns have been raised about the plant's toxicity, specifically related to the presence of solanine alkaloids. The leaves of Cestrum nocturnum contain atropine-like anticholinergic alkaloids; the unripe berries contain solanine, while the ripe berries contain anticholinergic glycoside toxins. Published research also notes the presence of other alkaloid fractions (see Section 6, Safety).
3.5 Essential Oil and Volatile Compounds
The major compounds detected by GC-MS in the distilled flower oil were phenylethyl alcohol (27.45%), benzyl alcohol (12.21%), eicosane (5.62%), eugenol (5.59%), n-tetracosane (4.42%), caryophyllene oxide (3.15%), 1-hexadecanol (2.75%), methoxyeugenol (2.45%), and benzaldehyde (2.32%).
Analysis of the floral absolute by GC and GC/MS produced a broader profile. Olfactorily valuable compounds found at concentrations higher than 1% included linalool (3.1%), benzaldehyde (2.5%), benzyl alcohol (2.4%), phenylacetaldehyde (2.4%), cis-jasmone (2.1%), benzyl acetate (1.8%), phenol (1.6%), methyl jasmonate (1.5%), 1,8-cineole (1.4%), borneol (1.3%), eugenol (1.3%), linalyl acetate (1.2%), and citronellyl propionate (1.1%), in addition to more than 70 other volatiles, more than 10 higher hydrocarbons (>C16), and more than 10 fatty acids and their esters.
The phenylpropanoid biosynthesis pathway contains the seven key floral scent components of C. nocturnum: benzaldehyde, phenyl acetaldehyde, phenylethyl alcohol, benzyl alcohol, benzyl acetate, methyl benzoate, and eugenol. Benzaldehyde, phenyl acetaldehyde, and benzyl acetate were identified as the main floral scent substances involved in this pathway.
3.6 Calcinogenic Glycosides
Mature leaves hold a calcinogenic glycoside that can lead to vitamin D toxicity and is accountable for elevated serum calcium levels. This is primarily a concern for livestock (see Section 6). It should be noted that the well-characterized 1,25-dihydroxyvitamin D₃-glycoside is most definitively associated with the closely related species Cestrum diurnum; Cestrum nocturnum, along with C. aurantiacum and C. parqui, causes toxicity in livestock through the action of atropine-like alkaloids, and these species of Cestrum have not been associated with calcinosis.
3.7 Other Phenolic Compounds
Phytochemical analysis of chloroform fractions of methanol extract of C. nocturnum aerial parts has shown the presence of triterpenes, coumarins, and flavonoids. Chlorogenic acid — a potent sensitizer — has also been reported. Some Cestrum species contain chlorogenic acid, and the presence of this potent sensitizer may be responsible for respiratory sensitization effects in C. nocturnum.
4. Mechanisms of Action
4.1 Enzyme Inhibition (Antidiabetic / Neuroprotective)
Research has investigated the therapeutic potential of C. nocturnum leaf extracts against diabetes and neurological disorders via targeting of α-amylase and acetylcholinesterase (AChE) activities, followed by computational molecular docking studies. The methanolic fraction exhibited the strongest antioxidant potential against DPPH (IC₅₀ 39.12 ± 0.53 µg/mL) and ABTS (IC₅₀ 20.94 ± 0.82 µg/mL) radicals, and strongly inhibited α-amylase (IC₅₀ 188.77 ± 1.67 µg/mL) and AChE (IC₅₀ 239.44 ± 0.93 µg/mL) in a non-competitive and competitive manner, respectively. These enzyme inhibition data are from in vitro and in silico studies only.
4.2 Cytotoxicity: DNA Damage and Topoisomerase II Inhibition
Fractions C4 and C5 extracted from the n-butanol part of C. nocturnum flowers were found to exhibit great cytotoxicity to cancer cell lines but had low immune toxicity towards T and B lymphocytes in vitro. A previous study demonstrated that the n-butanol part isolated from the flowers produced an inhibitory effect on the proliferation of human hepatocellular carcinoma Bel-7404, human gastric carcinoma SGC-7901, and cervical cancer HeLa cells in a dose-dependent manner. The proposed mechanism involves DNA damage induction and inhibition of topoisomerase II activity. All of this evidence is preclinical (cell-line based) with no human data.
4.3 Antimicrobial Mechanisms
Studies evaluated the antibacterial, antifungal, and cytotoxic effects of chloroform, ethyl acetate, and aqueous fractions from C. nocturnum methanol extract, finding that the chloroform fraction had the highest antibacterial effect and cytotoxicity against lung, colon, and hepatocellular carcinoma cell lines, while the ethyl acetate fraction displayed the highest antifungal activity and cytotoxicity against cervical carcinoma cell lines. The crude extract and fractions demonstrated activity against Candida species and M. canis, with minimum inhibitory concentrations (MICs) for various fungi ranging from 170 to 290 µg/mL.
4.4 Central Nervous System Effects
Local anesthetic effect, inhibitory effect on the central nervous system, and cardiac arrhythmic effects have been documented in the literature. These effects are attributed to the alkaloid constituents of the plant and remain characterized only in preclinical models.
4.5 Wound Healing: Hydroxyproline and Collagen Synthesis
High rates of wound contraction (p < 0.001), decreased period for epithelialization (p < 0.01), high skin breaking strength (p < 0.001), and elevated hydroxyproline content were observed in animals treated with ethanolic extract of C. nocturnum (EECN) ointments compared to control groups. These findings are consistent with promotion of collagen synthesis, but again are confined to animal models.
5. Scientific Evidence by Area of Health Use
Important caveat: As of the time of writing, the entire body of pharmacological evidence for Cestrum nocturnum consists of in vitro (cell-based), in vivo (animal model), and in silico (computational) studies. The plant shows great potential as a source of bioactive compounds that could have valuable therapeutic applications; however, more research is needed, including thorough clinical trials and toxicity assessments, to determine the safety and effectiveness of this treatment for specific conditions. No completed, peer-reviewed human clinical trials have been identified.
5.1 Antidiabetic and Antihyperglycemic Activity
Evidence level: Preclinical (animal) only.
One published study investigated the antidiabetic activity of hydroalcoholic extract of Cestrum nocturnum leaves in Wistar rats; leaves extract was prepared by Soxhletation method; rats were made diabetic by a single dose of streptozotocin (150 mg/kg i.p.); and the extract was administered to streptozotocin-induced diabetic rats at concentrations of 200 mg/kg and 400 mg/kg body weight in groups of 6 diabetic rats orally once a day for 15 days. Metformin was also administered to a parallel group at a dose of 10 mg/kg body weight orally once a day for 15 days.
Separately, an in vitro and in silico study found that the methanolic leaf extract strongly inhibited α-amylase (IC₅₀ 188.77 ± 1.67 µg/mL) in a non-competitive manner. This suggests capacity to be employed as a medicine for diabetes and highlights the importance of natural inhibitors in C. nocturnum for managing post-meal hyperglycemia. However, all antidiabetic evidence is from animal models and in vitro enzyme assays; no human data exist.
5.2 Anticancer / Cytotoxic Activity
Evidence level: Preclinical (cell-line) only.
The cytotoxic activities of isolated flavonol glycosides and steroidal saponins from the leaves of C. nocturnum were tested against human oral squamous cell carcinoma cells (HSC-2) and normal human gingival fibroblasts. These in vitro assays demonstrated selective cytotoxic activity against cancer cell lines. The n-butanol flower fraction produced an inhibitory effect on the proliferation of human hepatocellular carcinoma Bel-7404, human gastric carcinoma SGC-7901, and cervical cancer HeLa cells in a dose-dependent manner — also observed solely in cell culture. The chloroform fraction showed the highest cytotoxicity against lung, colon, and hepatocellular carcinoma cell lines, while the ethyl acetate fraction displayed the highest cytotoxicity against cervical carcinoma cell lines. None of this constitutes clinical evidence of anticancer efficacy in humans.
5.3 Antimicrobial Activity
Evidence level: Preclinical (in vitro microbiological assays) only.
Crude extract and fractions of C. nocturnum demonstrated activity only against Candida species and M. canis, with MICs for various fungi ranging from 170 to 290 µg/mL. Several published studies have assessed antibacterial and antifungal effects using disc diffusion and broth dilution methods. One study found that the maceration method produced the highest phenol content (56.763 ± 1.583 mg GAE/g DS), and C. nocturnum showed higher antioxidant values (229.247 ± 7.259 μmol Trolox/g DS) compared to Nerium oleander. Evidence is limited to in vitro testing; no clinical antimicrobial efficacy data exist.
5.4 Anticonvulsant and Neurological Effects
Evidence level: Preclinical only; traditional use reported.
In Mexican folk medicine, an extract of the leaves is used as an antispasmodic, especially in the treatment of epilepsy. Preclinical pharmacological studies have tested anticonvulsant, antiepileptic, and local anesthetic properties. Reported effects in preclinical literature include anticonvulsant, antiepileptic, local anesthetic, antihyperglycemic, antihyperlipidemic, pesticidal, wound healing, antiarrhythmic, and antitumor effects. No human clinical trial data on anticonvulsant efficacy have been published.
5.5 Wound Healing
Evidence level: Preclinical (rodent) only.
One published study investigated the wound healing effect of ethanolic extract of Cestrum nocturnum leaves (EECN) using excision and incision wound models in Wistar albino rats. The study used five groups of six animals each: untreated control, ointment base negative control, 5% povidone iodine ointment standard group, EECN 2% (w/w) ointment group, and EECN 5% (w/w) ointment group. Different concentrations of EECN (2% and 5% w/w) ointment promoted wound healing activity significantly in both models; high rates of wound contraction (p < 0.001), decreased epithelialization period (p < 0.01), high skin breaking strength (p < 0.001), and elevated hydroxyproline content were observed compared to controls. The ethanolic extract of C. nocturnum leaves possesses a concentration-dependent wound healing effect in this rodent model. Human evidence is absent.
5.6 Antioxidant Activity
Evidence level: In vitro only.
The methanolic fraction of sequentially extracted C. nocturnum leaves exhibited the strongest antioxidant potential against DPPH (IC₅₀ 39.12 ± 0.53 µg/mL) and ABTS (IC₅₀ 20.94 ± 0.82 µg/mL) radicals. Multiple studies have characterized antioxidant properties by standard radical-scavenging assays (DPPH, ABTS), attributing these effects to the phenolic, flavonoid, and saponin content of the plant. All data are in vitro.
5.7 Antifungal Activity Against Plant Pathogens
Pennogenin tetraglycoside isolated from Cestrum nocturnum (Solanaceae) has been studied for antifungal activity against Fusarium kuroshium, the causal agent of Fusarium dieback. This represents a potential agricultural rather than human health application, and the evidence is preclinical.
5.8 Antianxiety and Antidepressant Effects
Evidence level: Preclinical (animal) only; studies cited but details limited.
Published studies have investigated the evaluation of antianxiety and antidepressant activity of Cestrum nocturnum leaves in animal models. No results from human trials are available.
5.9 Larvicidal Activity
Extracts of C. nocturnum have shown larvicidal activity against the mosquito Aedes aegypti, with no observed toxicity to fish. This is a non-human application studied in the context of vector control biology.
6. Body Systems and Health Areas Associated with Cestrum nocturnum
- Metabolic / Endocrine system: Antidiabetic, antihyperglycemic, and antihyperlipidemic effects studied in animal models and in vitro enzyme assays.
- Nervous system: Anticonvulsant, sedative, antianxiety, antidepressant, local anesthetic, and AChE-inhibitory (potential neuroprotective) effects — all preclinical.
- Integumentary system (skin): Wound healing in rodent models; traditional use for skin irritations.
- Oncology (preclinical): In vitro cytotoxic activity demonstrated against hepatocellular, gastric, cervical, lung, oral, and colon cancer cell lines.
- Microbiology / Infectious disease: Antibacterial and antifungal activity in vitro.
- Digestive system: Traditional use in Chinese medicine for digestive complaints; hepatoprotective and nephrocurative activities reported in preclinical literature.
- Respiratory system: Traditional use of steam inhalation for colds; a sensitizer (chlorogenic acid) in the plant may adversely affect this system in sensitive individuals.
- Cardiovascular system: Antiarrhythmic and cardiac-inhibitory effects documented in preclinical studies.
- Perfumery / Aromatherapy: Floral essential oil and absolute used in fragrance; no clinical evidence for aromatherapeutic efficacy.
7. Dosage Forms and Dosages Reported in Studies
No standardized dosage for human use has been established. The following are dosages as used specifically in the cited preclinical studies.
- Antidiabetic animal study (Kamboj et al., 2013): Hydroalcoholic leaf extract of Cestrum nocturnum was given to streptozotocin-induced diabetic rats at concentrations of 200 mg/kg and 400 mg/kg of body weight orally once a day for 15 days.
- Wound healing animal study: Groups of Wistar albino rats were treated with 2% (w/w) and 5% (w/w) EECN ointment (ethanolic leaf extract), with all treatments given once daily.
- Flower essential oil (GC-MS characterization): Hydrodistillation of air-dried flowers gave a dark yellowish oil with a yield of 0.34% (w/w).
- Antioxidant / enzyme inhibition (in vitro, 2023 PMC study): The methanolic fraction inhibited DPPH radicals at IC₅₀ 39.12 ± 0.53 µg/mL, ABTS at IC₅₀ 20.94 ± 0.82 µg/mL, α-amylase at IC₅₀ 188.77 ± 1.67 µg/mL, and AChE at IC₅₀ 239.44 ± 0.93 µg/mL.
- Antiviral (in vitro): An IC₅₀ of 10.93 µg/mL has been reported for activity against HCoV-229E.
- Antifungal (in vitro, Rashed et al., 2018): Minimum inhibitory concentrations (MICs) for various fungi ranged from 170 to 290 µg/mL.
8. Safety Considerations and Interactions
8.1 General Toxicity Status
C. nocturnum human ingestion has not been well documented, but caution is recommended. The fruits and leaves of this species are known to be poisonous. Some plant guides describe C. nocturnum as "toxic" and warn that ingesting plant parts, especially fruit, may result in elevated temperature, rapid pulse, excess salivation, and gastritis.
8.2 Solanine and Anticholinergic Alkaloid Toxicity
Clinical features of poisoning by this plant are due to two forms of toxic agents: anticholinergic alkaloid intoxication and glycoalkaloid poisoning from solanine. Acute symptoms of anticholinergic poisoning include dry mouth, dysphagia, dystonia, tachycardia, and urine retention, followed by hyperthermia with flushed and dry skin; neurological symptoms occurring later include blurred vision, excitement and delirium, headache, and confusion. Dehydration and electrolyte imbalance are main features of solanine poisoning.
8.3 Documented Cases of Adverse Effects
Reports exist of children who ate significant quantities (handfuls) of berries with no significant effects, and two further cases where berries were ingested in smaller amounts with similar negative results. However, a more serious case is documented: a 2-year-old child who ingested green berries over several weeks developed diarrhea, vomiting, and blood clots in the stool, alongside anemia and purpura; a solanine alkaloid isolated from the child's stool was found to be hemolytic to human red blood cells.
While poisoning from this plant can pose serious effects on humans especially children, reported cases of poisoning are rather rare.
8.4 Respiratory Sensitization from Floral Scent
The most commonly reported problems associated with C. nocturnum are respiratory problems from the scent, and feverish symptoms following ingestion; some people, especially those with respiratory sensitivities or asthma, have reported difficulty breathing, irritation of the nose and throat, headache, nausea, or other symptoms when exposed to the blossom's powerful scent. Some Cestrum species contain chlorogenic acid, and the presence of this potent sensitizer may be responsible for this effect in C. nocturnum.
8.5 Livestock Toxicity
Cestrum nocturnum, along with C. aurantiacum and C. parqui, causes toxicity in livestock through the action of atropine-like alkaloids that are common in the family Solanaceae. These species of Cestrum have not been associated with calcinosis (which is more definitively the concern with Cestrum diurnum). According to one documented report, ingesting 15 lb of plant material caused a cow to salivate, clamp its jaws, collapse, and eventually die; postmortem showed gastroenteritis and congestion of liver, kidneys, brain, and spinal cord.
8.6 Invasive Ecology
The plant has escaped cultivation and is considered an aggressive weed or invasive in many parts of Oceania, including Australia, New Zealand, Fiji, French Polynesia, New Caledonia, and Samoa; seeds are spread by birds, and the shrubs can form dense thickets and crowd out native vegetation.
8.7 Known Drug Interactions and Safety Gaps
No formal human pharmacokinetic data or interaction studies between Cestrum nocturnum preparations and pharmaceutical drugs have been published in the peer-reviewed literature. The presence of anticholinergic alkaloids suggests a theoretical potential for additive effects with other anticholinergic drugs, but this has not been systematically evaluated. More research is needed, including thorough clinical trials and toxicity assessments, to determine the safety and effectiveness of this plant for specific conditions.
9. Brunfelsia americana: The Other "Lady of the Night"
Brunfelsia americana, which shares the common name "Lady of the Night" in many Caribbean and North American contexts, is a distinct species within the same family (Solanaceae). It is native to the West Indies. This species is the most aromatic of all the Brunfelsia species. It is a large shrub growing 5–10 ft tall with pale yellow, star-shaped flowers that release a strong, sweet scent at night. Brunfelsia americana is chemically and pharmacologically distinct from Cestrum nocturnum. Scientific research specifically on Brunfelsia americana as a dietary supplement or medicinal ingredient is sparse and is not covered in the authoritative peer-reviewed pharmacological literature surveyed for this article.
10. Summary of Evidence Strength
Cestrum nocturnum shows great potential as a source of bioactive compounds that could have valuable therapeutic applications; however, more research is needed, including thorough clinical trials and toxicity assessments, to determine the safety and effectiveness of treatment for specific conditions. The significance of combining traditional knowledge with scientific validation must be emphasized alongside prioritizing safe utilization.
The table below summarizes the state of evidence for each major area:
- Antidiabetic/antihyperglycemic: Animal and in vitro/in silico data only. No human trials.
- Anticancer/cytotoxic: In vitro cell-line data only. No human trials.
- Antimicrobial: In vitro microbiological assays only. No clinical trials.
- Anticonvulsant/antiepileptic: Traditional use; preclinical animal models. No human trials.
- Wound healing: Rodent excision/incision models. No human trials.
- Antioxidant: In vitro assays (DPPH, ABTS) only.
- Antianxiety/antidepressant: Preclinical animal models only. No human trials.
- Fragrance/aromatherapy: Chemical characterization of volatile profile is well established; clinical efficacy for aromatherapeutic applications is not demonstrated.
- Safety (toxicity): Solanine and anticholinergic alkaloid content confirmed; isolated case reports of human poisoning; no systematic clinical toxicology studies in humans.
References
Go back